3-碘-6-甲氧基-2-(三氟甲基)吡啶 | 503184-34-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 3-碘-6-甲氧基-2-(三氟甲基)吡啶
• 英文名称: 3-iodo-6-methoxy-2-(trifluoromethyl)pyridine
• CAS: 503184-34-7
• 化学式: C₇H₅F₃INO
• mdl: MFCD09744139
• 分子量: 303.023
• InChiKey: OALNBVZKAAUOCT-UHFFFAOYSA-N

物化性质

• 沸点：
  234.5±40.0 °C(Predicted)
• 密度：
  1.867±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.285
• 拓扑面积：
  22.1
• 氢给体数：
  0
• 氢受体数：
  5

安全信息

• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  3-碘-6-甲氧基-2-(三氟甲基)吡啶 在 ammonium hydroxide 、 sodium dithionite 、 氢溴酸 、 三氟乙酸 、 锌 、 三氯氧磷 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 乙腈 为溶剂， 反应 160.33h， 生成 5-[2-Ethyl-3-(1-methyl-butyl)-3H-imidazo[4,5-b]pyridin-7-yl]-6-trifluoromethyl-pyridin-2-ol
  参考文献：
  名称：

  CRF Ligands via suzuki and negishi couplings of 3-pyridyl boronic acids or halides with 2-benzyloxy-4-chloro-3-nitropyridine

  摘要：

  A series of imidazo[4,5-b]pyridines with a 7-(3-pyridyl) substituent is described as high affinity CRF receptor ligands. Individual analogues were synthesized from key intermediates obtained via palladium-catalyzed coupling of 3-pyridyl zinc or boronic acid organometallic intermediates with 2-benzyloxy-4-chloro-3-nitropyridine 12. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00835-1
• 作为产物：
  描述：

  6-甲氧基-3-硝基-2-(三氟甲基)吡啶 在 盐酸 、 ammonium hydroxide 、 sodium dithionite 、 sodium nitrite 作用下， 以 1,4-二氧六环 为溶剂， 反应 48.0h， 生成 3-碘-6-甲氧基-2-(三氟甲基)吡啶
  参考文献：
  名称：

  CRF Ligands via suzuki and negishi couplings of 3-pyridyl boronic acids or halides with 2-benzyloxy-4-chloro-3-nitropyridine

  摘要：

  A series of imidazo[4,5-b]pyridines with a 7-(3-pyridyl) substituent is described as high affinity CRF receptor ligands. Individual analogues were synthesized from key intermediates obtained via palladium-catalyzed coupling of 3-pyridyl zinc or boronic acid organometallic intermediates with 2-benzyloxy-4-chloro-3-nitropyridine 12. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00835-1

文献信息

• [EN] BICYCLIC FUSED PYRIDINE COMPOUNDS AS INHIBITORS OF TAM KINASES<br/>[FR] COMPOSÉS DE PYRIDINE BICYCLIQUES FUSIONNÉS UTILISÉS EN TANT QU'INHIBITEURS DE KINASES TAM
  申请人：ARRAY BIOPHARMA INC

  公开号：WO2019113190A1

  公开（公告）日：2019-06-13

  Provided herein are compounds of the Formula (I): and stereoisomers, tautomers and pharmaceutically acceptable salts thereof, wherein Ring A, X1, X2, X3, R1, R2 and R3 are as defined herein, which are inhibitors of one or more TAM kinases and are useful in the treatment and prevention of diseases which can be treated with a TAM kinase inhibitor.

  本文提供了Formula (I)的化合物及其立体异构体、互变异构体和药用可接受的盐，其中环A、X1、X2、X3、R1、R2和R3如本文所定义，这些化合物是一种或多种TAM激酶的抑制剂，并且在治疗和预防可以用TAM激酶抑制剂治疗的疾病中非常有用。
• [EN] COMPOUNDS AS CRF1 RECEPTOR ANTAGONISTS<br/>[FR] COMPOSES UTILISES COMME ANTAGONISTES DU RECEPTEUR DE TYPE 1 DE LA CORTICOLIBERINE (CRF)
  申请人：UPJOHN CO

  公开号：WO2004099201A1

  公开（公告）日：2004-11-18

  The present invention relates to compounds of Formula I,or a stereoisomer thereof, a pharmaceutically acceptable salt thereof, or a prodrug thereof. The compounds of the inventions are CRF, receptor antagonists. Compounds of the invention are useful for treating, in a warm-blooded animal, particularly a mammal, and more particularly a human, various disorders that are associated with CRF or CRF, receptors, or disorders the treatment of which can be effected or facilitated by antagonizing CRF, receptors.

  本发明涉及公式I的化合物，或其立体异构体，其药学上可接受的盐，或其前体。本发明的化合物是CRF受体拮抗剂。本发明的化合物可用于治疗温血动物，尤其是哺乳动物，更特别是人类，与CRF或CRF受体相关的各种疾病，或者通过拮抗CRF受体来治疗或促进治疗的疾病。
• Compounds as CRF1 receptor antagonists
  申请人：Corbett W. Jeffrey

  公开号：US20050038040A1

  公开（公告）日：2005-02-17

  The present invention relates to compounds of Formula I, or a stereoisomer thereof, a pharmaceutically acceptable salt thereof, or a prodrug thereof. The compounds of the inventions are CRF 1 receptor antagonists. Compounds of the invention are useful for treating, in a warm-blooded animal, particularly a mammal, and more particularly a human, various disorders that are associated with CRF or CRF 1 receptors, or disorders the treatment of which can be effected or facilitated by antagonizing CRF 1 receptors.

  本发明涉及公式I的化合物，或其立体异构体，其药学上可接受的盐或前药。本发明中的化合物是CRF1受体拮抗剂。本发明中的化合物可用于治疗温血动物，特别是哺乳动物，更特别是人类，与CRF或CRF1受体相关的各种疾病，或通过拮抗CRF1受体来实现或促进治疗的疾病。
• Bicyclic fused pyridine compounds as inhibitors of TAM kinases
  申请人：ARRAY BIOPHARMA INC.

  公开号：US11247990B1

  公开（公告）日：2022-02-15

  Provided herein are compounds of the Formula (I): and stereoisomers, tautomers and pharmaceutically acceptable salts thereof, wherein Ring A, X1, X2, X3, R1, R2 and R3 are as defined herein, which are inhibitors of one or more TAM kinases and are useful in the treatment and prevention of diseases which can be treated with a TAM kinase inhibitor.

  本文提供了式（I）化合物：及其立体异构体、同系物和药学上可接受的盐，其中环 A、X1、X2、X3、R1、R2 和 R3 如本文所定义，它们是一种或多种 TAM 激酶的抑制剂，可用于治疗和预防可使用 TAM 激酶抑制剂治疗的疾病。
• COMPOUNDS AS CRF1 RECEPTOR ANTAGONISTS
  申请人：Pharmacia & Upjohn Company LLC

  公开号：EP1625125A1

  公开（公告）日：2006-02-15